Tirzepatide seeks to resolve the dilemma of losing weight.
The little-known yet emerging peptide has been impressive in recent clinical trials.
As a result, more fitness and medical experts are becoming advocates of the peptide.
Discover 8 things to know about Tirzepatide:
Table of Contents
What Is Tirzepatide Peptide?
Note: This is a review. Click Here to pick up Tirzepatide from our #1 rated source, Core Peptides.
Unfortunately, people do not fail diets but diets fail them.
As a result, many men and women have been seeking to find a weight loss alternative to traditional diets and exercise programs.
Tirzepatide has received a lot of attention of late due to how the peptide has performed in clinical trials (more details, below).
However, before you use Tirzepatide, it’s important to keep several things in mind regarding the peptide, such as:
- Purpose
- How It Works
- History
- Weight Loss
- Type II Diabetes
- Tirzepatide Results
- How to Use
- Side Effects
Tirzepatide was recently approved for medical use in the United States.
The U.S. Food and Drug Administration (FDA) considers the peptide a first-in-class medication with much potential to transform bodies.
Learn 8 things you should know about Tirzepatide, below:
#1. Purpose
Obesity is a huge issue not just in the United States, but the world.
According to data, there are more than 650 million overweight adults making it the most prominent chronic disease on the globe.
Obesity contributes to a wide range of health problems including diabetes and stroke.
For this reason, Tirzepatide was first introduced for the treatment of type II diabetes.
However, multiple studies (more information, below) have demonstrated that Tirzepatide also assists with appetite suppression and weight loss.
Therefore, the primary purposes of Tirzepatide are treating diabetes, losing weight, and controlling appetite.
It’s designed to supplement a traditional diet and workout program with the eventual goal of burning fat and replacing it with lean muscle.
The FDA-approved medication decreases blood sugar levels while increasing insulin production.
Furthermore, the peptide lowers the amount of sugar in the liver which also slows down the rate of food passing through the body.
Consequently, individuals feel fuller for longer and therefore are able to control hunger cravings.
Tirzepatide is used on its own (single therapy) along with other peptides and supplements.
The peptide is administered through subcutaneous injection (see, How to Use).
#2. How It Works
Tirzepatide is an analog of gastric inhibitory polypeptide (GIP) receptors.1
These hormones play a critical role in the release of insulin from the pancreas.
Furthermore, GIP receptors are integral to optimizing metabolism – a primary component in weight loss.2
Tirzepatide also influences the GLP-1 receptors in the body, another method for regulating blood sugar in the body.3
And, when combined into one treatment, is capable of helping individuals lose weight and control hunger cravings.
It’s often combined with a healthy diet and workout program to maximize results.
Tirzepatide recently completed phase III clinical trials in 2021, and has received FDA approval as a medication for type II diabetes.
However, the peptide has not been approved for weight loss yet which is likely to change in the near future given the impressive results (see, below).
#3. History
Tirzepatide has recently come into the spotlight after several notable achievements.
Eli Lilly and Company first applied to patent the diabetes treatment in 2016.
Then, after completing phase III clinical trials, was approved by the FDA in October of 2021.4
Tirzepatide received “priority review” status from the FDA which means the review process was expedited due to early, promising results.
The FDA approved the substance based on evidence from 9 clinical trials, all of which were encouraging for those suffering from diabetes and/or obesity.5
In fact, nearly 5,500 participants were examined in 24 different countries, including the United States, Canada, Japan, Australia, and South Korea.
Ultimately, the company announced in April of 2022 that the peptide has met all the necessary requirements for clinical testing.
Currently, Tirzepatide is often compared to Semaglutide, another injectable form of treatment for obesity.6
Despite it, a 2021 meta-analysis discovered that Tirzepatide was far more effective and successful compared to other treatments.7
#4. Tirzepatide & Weight Loss
First and foremost, Tirzepatide was developed as a treatment for type II diabetes.
Be that as it may, the peptide has also shown remarkable potential for helping men and women lose weight and keep the pounds off for good.8
Tirzepatide has proven effective in phase III clinical trials, even more so compared to other more well-known antiobesity treatments.9
In fact, the average participant lost 15% of total weight (5mg, weekly dose) while the weight loss was even better at higher doses (20% at 10mg).
Even better, clinical research has led to even more discoveries regarding the powerful peptide.
For example, Tirzepatide has been shown to delay gastric emptying, contributing to fewer cravings and appetite suppression.10
As a result, the FDA recently declared “fast track” status for the peptide in order to speed up clinical trials.
Therefore, it’s conceivable that Tirzepatide will soon be an FDA-approved medication for obesity and weight loss.
#5. Tirzepatide & Diabetes
The initial purpose of Tirzepatide was to find a better alternative to other treatments for type II diabetes.
And, thus far, the results have been more promising compared to other synthetic GLP-1R agonists.
Research indicates that Tirzepatide not only releases more insulin in the pancreas but also reduces inflammation in adipose tissue.11
Moreover, the peptide modulates adiponectin levels which reduces fat cell differentiation (among other benefits).
Low adiponectin levels are associated with type II diabetes and other diseases like atherosclerosis.12
Be that as it may, Tirzepatide has not been tested on individuals who have had pancreatitis.
Additionally, the treatment is only designated for type II diabetes, not type I diabetes.
Nevertheless, in less than 10 years of research, Tirzepatide has already demonstrated better results compared to strict GLP-1R agonists for diabetes.13
#6. Tirzepatide Results
Tirzepatide received FDA approval as a treatment for type II diabetes following the success of 9 clinical trials.
All in all, nearly 8,000 subjects were studied in clinical trials that took place all over the globe.
The 9 clinical trials were used to assess the safety of Tirzepatide while 5 of these experiments focused more on the efficacy.
These 5 trials examined 6,263 participants with type II diabetes which contributed to the first breakthroughs in weight loss research.
Participants were randomly assigned either Tirzepatide or a placebo injection once a week.
The patient and healthcare provider were not made aware whether they were receiving the peptide or not.
Treatment for the first 5 trials lasted 40 weeks and produced impressive results.
Moreover, the other 3 clinical trials consisted of participants receiving either Tirzepatide or another antidiabetic medication.
Treatment for these trials spanned from 40 weeks to 104 weeks.
Multiple discoveries found that Tirzepatide has the potential to impact weight reduction as well as control appetite / hunger cravings.14
Nonetheless, the most impressive discovery thus far is a 2021 meta-analysis that found Tirzepatide is far superior to other antiobesity treatments, including:
- Semaglutide
- Dulaglutide
- Degludec
- Insulin Glargine
However, researchers do not believe that we have learned all there is to know about Tirzepatide and many other peptides.15
In fact, recent evidence suggests that Tirzepatide may improve many cardiac functions, including reduced risk of heart disease.
For this reason, the peptide may eventually one day regulate hypertension and other heart issues related to obesity.
#7. How to Use
Tirzepatide is generally sold in lyophilized powder and transformed into a liquid solution.
Next, it’s usually administered 1x per week via subcutaneous (under the skin) injection.
It’s okay to use Tirzepatide with or without meals and does not require a certain administration schedule (mornings, nights, etc.).
In general, the peptide is injected into the thigh, abdomen, or upper arm.
Often, users rotate the site of injection in order to avoid aggravating one part of the body.
Weight loss supplements usually produce some irritation and bruising at the injection site.
The best advice is to start with a low dose (2 – 5mg) and gradually increase at a rate not more than once every 4 weeks.
Users must make sure that they spread doses between 3 – 5 days.
It’s okay to still use insulin so long as it’s not mixed with Tirzepatide or injected at the same site.
Tirzepatide controls type II diabetes yet is not known to cure it.
Consequently, it may take 4 – 6 weeks to notice any positive results from the peptide.
Before using Tirzepatide, inform your physician of any known allergies or other medications.
It’s also important to inform the doctor of any pre-existing kidney or pancreas condition.
Tirzepatide is only designated for adults and should not be used if you are pregnant or breastfeeding.
Additionally, the peptide has been shown to interfere with certain types of birth control medication.
It’s crucial to store Tirzepatide in a refrigerator and away from direct sunlight.
Click Here to pick up Tirzepatide from our #1 rated source, Core Peptides.
#8. Side Effects
Tirzepatide, like any supplement, has some associated risks and side effects.
In general, the most common side effects are minor and include nausea, decreased appetite, upset stomach, and abdominal discomfort / pain.
There are also reported cases of constipation, vomiting, and diarrhea yet not extremely common.
Nevertheless, beginning with a lower dosage can help avoid many of these unwanted complications.
Still, closely monitoring symptoms and discontinuing use can help avoid any serious side effects.
Tirzepatide may also cause low blood sugar or hypoglycemia.16
The symptoms of hypoglycemia include blurred vision, dizziness, sweating, confusion, and slurred speech.
Furthermore, some may notice spikes in anxiety or irritability, mood changes, or increased heart rate.
Tirzepatide is not designed for people with a history of thyroid cancer or pancreatitis.
Make sure you consult with a physician before starting any new supplement to avoid unwanted interactions with current medications.
Conclusion
What is Tirzepatide?
The peptide was first approved as a treatment for type II diabetes.
Since then, multiple other studies have concluded that Tirzepatide is also effective in controlling hunger cravings and weight loss.
For this reason, the substance is currently being “fast-tracked” to receive FDA approval as a type of antiobesity treatment.
References
- Fukuda M. The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. Diabetes. 2021 Sep;70(9):1929-1937. doi: 10.2337/dbi21-0001. Epub 2021 Jun 27. PMID: 34176784; PMCID: PMC8576424. (source)
- Fukuda M. The Role of GIP Receptor in the CNS for the Pathogenesis of Obesity. Diabetes. 2021 Sep;70(9):1929-1937. doi: 10.2337/dbi21-0001. Epub 2021 Jun 27. PMID: 34176784; PMCID: PMC8576424. (source)
- Andreasen CR, Andersen A, Knop FK, Vilsbøll T. How glucagon-like peptide 1 receptor agonists work. Endocr Connect. 2021 Jul 17;10(7):R200-R212. doi: 10.1530/EC-21-0130. PMID: 34137731; PMCID: PMC8346189. (source)
- FrÃas JP. An update on tirzepatide for the management of type 2 diabetes: a focus on the phase 3 clinical development program. Expert Rev Endocrinol Metab. 2023 Mar;18(2):111-130. doi: 10.1080/17446651.2023.2184796. Epub 2023 Mar 12. PMID: 36908082. (source)
- Hindson J. Tirzepatide to treat obesity: phase III results. Nat Rev Gastroenterol Hepatol. 2022 Aug;19(8):488. doi: 10.1038/s41575-022-00657-z. PMID: 35773392. (source)
- Chao AM, Tronieri JS, Amaro A, Wadden TA. Semaglutide for the treatment of obesity. Trends Cardiovasc Med. 2023 Apr;33(3):159-166. doi: 10.1016/j.tcm.2021.12.008. Epub 2021 Dec 21. PMID: 34942372; PMCID: PMC9209591. (source)
- Dutta D, Surana V, Singla R, Aggarwal S, Sharma M. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian J Endocrinol Metab. 2021 Nov-Dec;25(6):475-489. doi: 10.4103/ijem.ijem_423_21. Epub 2022 Feb 17. PMID: 35355921; PMCID: PMC8959203. (source)
- Chavda VP, Ajabiya J, Teli D, Bojarska J, Apostolopoulos V. Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review. Molecules. 2022 Jul 5;27(13):4315. doi: 10.3390/molecules27134315. PMID: 35807558; PMCID: PMC9268041. (source)
- Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, Kiyosue A, Zhang S, Liu B, Bunck MC, Stefanski A; SURMOUNT-1 Investigators. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4. PMID: 35658024. (source)
- Urva S, Coskun T, Loghin C, Cui X, Beebe E, O’Farrell L, Briere DA, Benson C, Nauck MA, Haupt A. The novel dual glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective long-acting GLP-1 receptor agonists. Diabetes Obes Metab. 2020 Oct;22(10):1886-1891. doi: 10.1111/dom.14110. Epub 2020 Jul 13. PMID: 32519795; PMCID: PMC7539915. (source)
- Frias JP, Nauck MA, Van J, Benson C, Bray R, Cui X, Milicevic Z, Urva S, Haupt A, Robins DA. Efficacy and tolerability of tirzepatide, a dual glucose-dependent insulinotropic peptide and glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes: A 12-week, randomized, double-blind, placebo-controlled study to evaluate different dose-escalation regimens. Diabetes Obes Metab. 2020 Jun;22(6):938-946. doi: 10.1111/dom.13979. Epub 2020 Feb 11. PMID: 31984598; PMCID: PMC7318331. (source)
- Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012 Feb;165(3):574-90. doi: 10.1111/j.1476-5381.2011.01395.x. PMID: 21457225; PMCID: PMC3315032. (source)
- Tate M, Chong A, Robinson E, Green BD, Grieve DJ. Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetes. Br J Pharmacol. 2015 Feb;172(3):721-36. doi: 10.1111/bph.12943. Epub 2014 Dec 1. PMID: 25231355; PMCID: PMC4301685. (source)
- Zhang Q, Delessa CT, Augustin R, Bakhti M, Colldén G, Drucker DJ, Feuchtinger A, Caceres CG, Grandl G, Harger A, Herzig S, Hofmann S, Holleman CL, Jastroch M, Keipert S, Kleinert M, Knerr PJ, Kulaj K, Legutko B, Lickert H, Liu X, Luippold G, Lutter D, Malogajski E, Medina MT, Mowery SA, Blutke A, Perez-Tilve D, Salinno C, Sehrer L, DiMarchi RD, Tschöp MH, Stemmer K, Finan B, Wolfrum C, Müller TD. The glucose-dependent insulinotropic polypeptide (GIP) regulates body weight and food intake via CNS-GIPR signaling. Cell Metab. 2021 Apr 6;33(4):833-844.e5. doi: 10.1016/j.cmet.2021.01.015. Epub 2021 Feb 10. PMID: 33571454; PMCID: PMC8035082. (source)
- Dutta D, Surana V, Singla R, Aggarwal S, Sharma M. Efficacy and safety of novel twincretin tirzepatide a dual GIP and GLP-1 receptor agonist in the management of type-2 diabetes: A Cochrane meta-analysis. Indian J Endocrinol Metab. 2021 Nov-Dec;25(6):475-489. doi: 10.4103/ijem.ijem_423_21. Epub 2022 Feb 17. PMID: 35355921; PMCID: PMC8959203. (source)
- Mathew P, Thoppil D. Hypoglycemia. [Updated 2022 Dec 26]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 Jan-. (source)
See Also
Semaglutide For Sale: 4 Trusted Vendors To Buy Online
Born and raised in Woodbridge, NJ, he graduated from the New Jersey Institute Of Technology with an MBA in eCommerce.His hobbies include beach volleyball, target shooting, and lifting.
Rob is also a Commercially rated pilot and Certified Flight Instructor (CFI), with over 1,500 hours of flight time.
- Pure Rawz Review: Legit Peptides & SARMS Or Fraud? - November 26, 2023
- American Flag With Circle Of Stars (Betsy Ross) Explained - November 23, 2023
- 20 Best Military War Movies Of All-Time - November 22, 2023
